Adacyte Therapeutics SL
2 clinical trials · Sponsor
◉ Watch Adacyte Therapeutics SL
| Record | Firm | Date |
|---|---|---|
| CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis (NCT05430412) | Adacyte Therapeutics SL | 2022-01-11 |
| National GMA Post-market Clinical Follow-up Study (GRACE) (NCT05636709) | Adacyte Therapeutics SL | 2022-01-11 |
Track Adacyte Therapeutics SL automatically
Every clearance here is in the API, with alerts when new ones post.